All In Biotech

Drug Trial Radar · NCT03760146

Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults

A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 YEARS OF AGE AND OLDER

Last checked: Nov 19, 2026Latest source record: Dec 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 3,902 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,902

Actual

Start

Dec 12, 2018

Primary completion

Dec 16, 2019

Study completion Dec 16, 2019

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Nov 30, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A Phase 3, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults

Conditions

  • Pneumococcal Disease

Interventions

  • 20vPnCBiological

    20vPnC

  • 13vPnCBiological

    Pneumococcal conjugate vaccine

  • PPSV23Biological

    Pneumococcal polysaccharide vaccine

  • SalineOther

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Local Reactions Within 10 Days After Vaccination in All CohortsTime frame: Within 10 days after 20vPnC or 13vPnC
  2. Percentage of Participants With Systemic Events Within 7 Days After Vaccination in All CohortsTime frame: Within 7 days after 20vPnC or 13vPnC
  3. Percentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination in All CohortsTime frame: Within 1 month after 20vPnC or 13vPnC
  4. Percentage of Participants With Serious Adverse Events (SAEs) Within 6 Months After Vaccination in All CohortsTime frame: Within 6 months after 20vPnC or 13vPnC
  5. Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) Within 6 Months After Vaccination in All CohortsTime frame: Within 6 months after 20vPnC or 13vPnC
  6. Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the 13 Matched Serotypes at 1 Month After Vaccination 1 (20vPnC or 13vPnC) in Cohort 1: Evaluable 13-Matched Immunogenicity PopulationTime frame: 1 month after Vaccination 1
  7. Pneumococcal OPA GMTs for the 7 Additional Serotypes at 1 Month After Vaccination 1 (20vPnC) or 1 Month After Vaccination 2 (PPSV23) in Cohort 1: Evaluable 7-Additional Immunogenicity Population (E7-AIP)Time frame: 1 month after Vaccination 1 in "Cohort 1: 20vPnC/Saline"; 1 month after Vaccination 2 in "Cohort 1: 13vPnC/PPSV23"

Locations

68 sites in 2 countries. Site status is shown where the registry gives one.

  • Accel Research Sites

    Birmingham, Alabama

  • Coastal Clinical Research, Inc.

    Mobile, Alabama

  • East Valley Gastroenterology and Hepatology Associates

    Chandler, Arizona

  • The Pain Center of Arizona

    Peoria, Arizona

  • MedPharmics, LLC

    Phoenix, Arizona

  • HOPE Research Institute

    Phoenix, Arizona

  • The Pain Center of Arizona

    Phoenix, Arizona

  • Anaheim Clinical Trials, LLC

    Anaheim, California

  • Diablo Clinical Research, Inc.

    Walnut Creek, California

  • Clinical Research Consulting, LLC

    Milford, Connecticut

  • Nature Coast Clinical Research

    Crystal River, Florida

  • Accel Research Sites - Clinical Research Unit

    DeLand, Florida

  • Research Centers of America, LLC

    Hollywood, Florida

  • Jacksonville Center for Clinical Research

    Jacksonville, Florida

  • Suncoast Research Group, LLC

    Miami, Florida

  • Acevedo Clinical Research Associates

    Miami, Florida

  • Qps-Mra, Llc

    South Miami, Florida

  • Atlanta Center for Medical Research

    Atlanta, Georgia

  • Meridian Clinical Research LLC

    Savannah, Georgia

  • Clinical Research Atlanta

    Stockbridge, Georgia

  • East-West Medical Research Institute

    Honolulu, Hawaii

  • Axtell Clinic, P.A.

    Newton, Kansas

  • Heartland Research Associates, LLC

    Newton, Kansas

  • Heartland Research Associates, LLC

    Wichita, Kansas

  • Northwest Family Physicians

    Wichita, Kansas

  • Heartland Research Associates, LLC

    Wichita, Kansas

  • Meridian Clinical Research, LLC

    Rockville, Maryland

  • Sundance Clinical Research

    St Louis, Missouri

  • Meridian Clinical Research, LLC

    Norfolk, Nebraska

  • Meridian Clinical Research LLC

    Omaha, Nebraska

  • ActivMed Practices & Research, Inc.

    Portsmouth, New Hampshire

  • United Medical Associates

    Binghamton, New York

  • Regional Clinical Research, Inc.

    Endwell, New York

  • Rochester Clinical Research, Inc.

    Rochester, New York

  • PharmQuest

    Greensboro, North Carolina

  • M3 Wake Research, Inc.

    Raleigh, North Carolina

  • PMG Research of Wilmington, LLC

    Wilmington, North Carolina

  • Lillestol Research LLC

    Fargo, North Dakota

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Sterling Research Group, Ltd.

    Cincinnati, Ohio

Showing 40 of 68 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.